      Document 0043
 DOCN  DRG0043
 UNIQUE IDENTIFIER        DRG-0204
 NAME OF SUBSTANCE        WF 10 [CHEMLINE]
 SYNONYMS                 TCDO [MeSH]
 SYNONYMS                 Tetrachlorodecaoxide [MeSH]
 SYNONYMS                 Tetrachlorodecaoxygen [MeSH]
 PROTOCOL ID NUMBERS      FDA 222A
 PROTOCOL ID NUMBERS      FDA 222B
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: In previous in vitro
                          experiments, oxoferin appeared to inactivate
                          HIV particles directly, but had no influence
                          on the intracellular replicative machinery of
                          HIV. [AIDS 1993 Sep;7(9)]
 DISEASES STUDIED/TREATED Primary HIV infection [FDA 222A]
 CLASSIFICATION CODE      Antiretroviral [FDA 222A]
 OTHER MAJOR USES         Promotion of wound healing, including ulcer
                          wounds [Lancet 1986 Apr 12; Vol 1] [The Extra
                          Pharmacopoeia 1993]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Chlorite-oxygen reaction
                          product [AIDS 1993 Sep;7(9)]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: Solution. [FDA 222A]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Intravenous. [FDA 222A]
 MANUFACTURERS            Oxo Chemie GmbH
 REFERENCES               Kempf SR, Blaszkiewitz K, Port RE, Ivankovic
                          S. Influence of tetrachlorodecaoxide (Ryoxon)
                          on the development of leukemia after
                          total-body gamma-irradiation. Oncology 1994
                          Nov-Dec;51(6):510-4.
 REFERENCES               Kempf SR, Port RE, Ivankovic S.
                          Anticarcinogenic effect of
                          tetrachlorodecaoxide after total-body gamma
                          irradiation in rats. Radiat Res 1994
                          Aug;139(2):226-31.
 REFERENCES               Busch HW, Christensen S, Reichelt D, Jahn S,
                          Zidek W. Treatment of HIV-infected patients
                          with advanced symptomatic disease with WF10
                          solution (TCDO). Int Conf AIDS. 1994 Aug
                          7-12;10(1):204 (abstract no. PB0245).
 REFERENCES               Ennen J, Werner K, Kuhne FW, Kurth R.
                          Inactivation of HIV infectivity by the
                          chlorite-oxygen reaction product
                          tetrachlorodecaoxygen. AIDS. 1993
                          Sep;7(9):1205-12.
 REFERENCES               Wolin MS, Kleber E, Mohazzab KM, Elstner EF.
                          Tetrachlorodecaoxygen, a wound healing agent,
                          produces vascular relaxation through
                          hemoglobulin-dependent inactivation of
                          serotonin and norepinephrine. J Cardiovasc
                          Pharmacol 1994 Apr;23(4):664-8.
 REFERENCES               Kempf SR, Blaszkiewitz K, Reim M, Ivankovic
                          S. Comparative study on the effects of
                          chlorite oxygen reaction product TCDO
                          (tetrachlorodecaoxygen) and sodium chlorite
                          solution (NaClO2) with equimolar chlorite
                          content on bone marrow and peripheral blood
                          of BDIX rats. Drugs Exp Clin Res
                          1993;19(4):165-74.
 REFERENCES               Mason KA, Murphy S, Milas L. Stimulation of
                          hematopoietic cell recovery by
                          tetrachlorodecaoxide in sublethally
                          irradiated mice. Radiat Res 1993
                          Nov;136(2):229-35.
 REFERENCES               Stoll P, Huber H, Pelz K, Weingart D.
                          Antimicrobial effects of the
                          tetrachlorodecaoxygen-anion complex on
                          oropharyngeal bacterial flora: an in vitro
                          study. Chemotherapy 1993;39(1):40-7.
 ENTRY MONTH              9403
 LAST REVISION DATE       960411
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
